H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140
H.C. Wainwright has reiterated its Buy rating on Mirum Pharmaceuticals (MIRM.US) and maintained its target price at $140. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy
H.C. Wainwright has reiterated a Buy rating and a $140.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM). The company's stock has seen a 53% gain over the past year, though InvestingPro analysis suggests it may be overvalued relative to its Fair Value despite recent earnings revisions. The article also mentions the FDA approval of Regeneron Pharmaceuticals' garetosmab for fibrodysplasia ossificans progressiva, a condition for which Mirum Pharmaceuticals' products are not directly related.
MIRM5806400 Bond Profile — Key Metrics
This article provides key metrics for the Mirum Pharmaceuticals, Inc. bond (MIRM5806400), detailing its 4.0% coupon rate and a maturity date of May 1, 2029. It outlines the bond's issue date, outstanding amount, face value, and minimum denomination. The company, Mirum Pharmaceuticals, is introduced as a biopharmaceutical firm focused on therapies for liver diseases.
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM
Lisanti Capital Growth LLC has acquired 63,295 shares of Mirum Pharmaceuticals (NASDAQ:MIRM) worth $7.41 million, making it their eighth-largest portfolio holding. Other institutional investors like BlackRock, Janus Henderson, State Street, and Wellington Management have also increased their positions. Despite missing quarterly EPS estimates and significant insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $137.33.
Mirum Pharmaceuticals(MIRM.US) Officer Sells US$4 Million in Common Stock
A Mirum Pharmaceuticals officer recently sold common stock valued at approximately $4 million. This transaction indicates a significant insider sale at the company.
Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares
Jolanda Howe, SVP, Global Controller at Mirum Pharmaceuticals (MIRM), exercised 40,000 employee stock options at $6.27 per share and subsequently sold all 40,000 common shares at $100.00 per share on August 18, 2026. This transaction resulted in an approximate pre-tax spread of $3.75 million. Following the transactions, Howe's stock option position was reduced to zero, while her direct common stock holdings stand at 1,274 shares.
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock
Jolanda Howe, SVP of Mirum Pharmaceuticals (NASDAQ:MIRM), sold 40,000 shares of the company's stock for $4 million on August 18th, reducing her stake by 96.91% to 1,274 shares. This sale follows several other transactions since June. The company's stock trades at $102.24 with a $6.64 billion market cap, and analysts maintain a "Moderate Buy" rating with an average price target of $137.33 despite missing recent EPS estimates.
Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M
Mirum Pharmaceuticals' SVP, Global Controller, Howe Jolanda, sold 40,000 shares of Common Stock for a total of $4,000,000 at $100.00 per share. Following this transaction, Jolanda directly owns 1,274 shares. This information is based on an SEC Form 4 filing and highlights an insider stock sale.
Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale
Jolanda Marie Howe, an officer at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), has filed a Form 144 to sell 40,000 common shares valued at $4,000,000.00 on August 18, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney. The filing also reports her previous sales of Mirum common stock in June, July, and August 2026.
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM
TimesSquare Capital Management LLC has invested $43 million in Mirum Pharmaceuticals, acquiring 367,281 shares. This move is part of broader institutional interest, even as some analysts have adjusted their ratings and price targets. Mirum Pharmaceuticals, a company focused on rare cholestatic liver diseases, reported strong revenue growth but wider-than-expected losses in its latest quarter, and insiders have sold approximately $9.8 million in stock.
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM
Rice Hall James & Associates LLC has acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), purchasing 110,673 shares valued at approximately $13.0 million. This comes as Mirum Pharmaceuticals reported a 37.9% increase in quarterly revenue year-over-year, reaching $176.24 million, although it also posted a larger-than-expected quarterly loss of $1.06 per share. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $137.33 for the stock.
Mirum Pharmaceuticals (MIRM) Losses Put Its Valuation Narrative Back In Focus
Mirum Pharmaceuticals (MIRM) reported wider net losses in Q2 and H1 2026, yet its share price has seen significant gains, up 28.91% year-to-date and 50.93% over one year. The company is currently trading at approximately $100, which analysts suggest is 30.2% undervalued with a consensus price target of $144.15, based on expectations of rapid revenue expansion and future profitability. However, risks like reimbursement decisions for Livmarli and trial results for VISTAS could alter this narrative.
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?
Mirum Pharmaceuticals (MIRM) reported widening net losses for Q2 and H1 2026, with a six-month net loss of US$857.38 million, intensifying focus on cash burn and funding risks. Despite promising late-stage assets and catalysts like a potential FDA approval for zilurgisertib, investors are evaluating whether rising R&D and SG&A costs will be offset by future revenues. Analysts project significant revenue and earnings by 2029, but the substantial losses highlight the company's high-investment, growth-focused narrative.
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?
Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as the FDA's Priority Review for zilurgisertib. Investors will need to assess whether the company's promising late-stage assets can offset rising R&D and SG&A expenses, especially given prior shareholder dilution.
Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell
Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a consensus of $0.74, and recent insider sales amounted to approximately $9.8 million. Despite the downgrade, the broader analyst consensus remains a "Moderate Buy" with a target price of $137.33.
Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News
Mirum Pharmaceuticals (MIRM) stock is currently considered fairly valued despite significant share price gains over the past five years. The company's P/S ratio of 10.4x is below the biotech industry average, suggesting it might still be on the inexpensive side. The future performance of the stock hinges on the continued revenue growth from LIVMARLI and progress in its broader pipeline.
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management
Janus Henderson Group Ltd., through its asset management subsidiaries, reported beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock, representing 9.7% of the class as of June 30, 2026. These shares are managed in client accounts (Managed Portfolios) where Janus Henderson holds shared voting and dispositive power, but the economic rights (dividends and sale proceeds) belong to the Managed Portfolios, with no single portfolio owning more than 5%. The filing clarifies that this ownership reflects aggregate holdings and is not intended to influence company control.
Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next
Mirum Pharmaceuticals (MIRM) saw its stock drop 6.4% despite raising its 2026 net product sales guidance, due to reporting significantly wider net losses in the second quarter of 2026. The company highlighted progress with breakthrough therapy designation for volixibat and potential launch timing for Zilurgisertib, indicating a strategic focus on long-term portfolio expansion despite immediate financial pressures. Investors are now scrutinizing cash burn and execution for future product launches, especially given the delay in volixibat's NDA.
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Mirum Pharmaceuticals, a rare disease company, announced it will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. The presentation will be webcast live on Mirum's corporate website. The company is known for its approved products for Alagille syndrome and progressive familial intrahepatic cholestasis, and has a pipeline of investigational medicines.
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 6,001 Shares of Stock
Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt sold 6,001 shares of the company's stock for approximately $599,500, reducing his direct ownership by 14.17%. This transaction was conducted under a pre-arranged Rule 10b5-1 plan. Despite the insider sale and an earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $137.33 for the rare disease biopharmaceutical company.
Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals (MIRM) reported strong Q2 2026 results with $176.2 million in net product sales, leading to an increased full-year guidance of $680 million to $700 million. The company is advancing its pipeline, including Zilurgisertib for FOP with a September PDUFA date, and addressing regulatory feedback from the FDA regarding volixibat for primary sclerosing cholangitis, which will delay its NDA submission to the first half of next year. Mirum also provided updates on other clinical programs, including brelovitug for chronic hepatitis delta virus and LIVMARLI for additional cholestatic conditions, with multiple key readouts anticipated soon.
Mirum Pharmaceuticals (MIRM) CFO sells 6,001 shares in Rule 10b5-1 trade
Mirum Pharmaceuticals' CFO, Eric Bjerkholt, sold 6,001 shares of common stock on August 11, 2026, at a weighted average price of $99.90 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on March 9, 2026. Following the sale, Bjerkholt beneficially owns 36,355 shares of Mirum common stock.
Mirum Pharmaceuticals CEO Christopher Peetz sells $1.98 million in shares
Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's common stock for approximately $1.98 million under a pre-arranged trading plan. Concurrently, he acquired 20,000 shares through the exercise of employee stock options for $58,720. Despite a recent stock pullback and an "overvalued" assessment by InvestingPro, the company reported strong Q2 net product sales and raised its 2026 sales outlook, though regulatory concerns caused a temporary stock drop.
Mirum Pharmaceuticals (NASDAQ:MIRM) CEO Christopher Peetz Sells 20,000 Shares of Stock
Mirum Pharmaceuticals CEO Christopher Peetz sold 20,000 shares of the company's stock for approximately $1.98 million on August 10th, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction reduced his direct ownership by 9.33% to 194,309 shares. Despite Mirum missing analysts' EPS estimates with a $1.06 loss per share, the company's revenue increased by 37.9% year-over-year, and analysts generally maintain a "Moderate Buy" rating with an average price target of $137.33.
Mirum Pharmaceuticals (MIRM) CEO trades 20,000 shares after option exercise under 10b5-1 plan
Mirum Pharmaceuticals, Inc. CEO Christopher Peetz exercised an employee stock option for 20,000 shares at $2.936 per share and subsequently sold all 20,000 shares in three tranches at weighted average prices between $98.51 and $100.14. These transactions, which occurred on August 10, 2026, were conducted under a Rule 10b5-1 Plan. Following the trades, Peetz holds 88,487 stock options and an indirect holding of 187,500 shares through The Peetz Family Trust.
MIRM (MIRM) insider files to sell 6,001 shares after recent stock sales
An insider at Mirum Pharmaceuticals (MIRM), Eric Bjerkh olt, has filed a notice to sell 6,001 shares of common stock with an aggregate market value of $599,509.50. This proposed sale follows two previous sales by the same insider within the last three months, totaling 10,000 shares for over $1 million. The shares to be sold are associated with restricted stock awards granted in September 2024 and January 2025.
Hennion & Walsh Asset Management Inc. Sells 56,100 Shares of Mirum Pharmaceuticals, Inc. $MIRM
Hennion & Walsh Asset Management Inc. reduced its stake in Mirum Pharmaceuticals (NASDAQ:MIRM) by 59.9%, selling 56,100 shares and retaining 37,492 shares valued at $4.39 million. This divestment occurred despite Mirum's Q2 revenue beating estimates and management raising its 2026 sales outlook. However, the company reported a wider-than-expected loss per share and faces potential delays due to an unexpected FDA request for a Phase 3 study.
Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC)
Two healthcare companies, Mirum Pharmaceuticals (MIRM) and Encompass Health (EHC), have received bullish analyst ratings. TD Cowen maintained a Buy rating for Mirum with a $140.00 price target, and a Strong Buy consensus suggests a 44.8% upside. Encompass Health also received a Buy rating from TD Cowen with a $140.00 price target, with analysts projecting a 19.9% upside.
MIRM (MIRM) insider Christopher Peetz plans 20,000-share sale after option exercise
Christopher Peetz, an insider at Mirum Pharmaceuticals (MIRM), has filed a Form 144 indicating his intent to sell 20,000 shares of common stock through Morgan Stanley Smith Barney LLC on or after August 10, 2026, following a stock option exercise. The filing also reports previous sales by Peetz, including 20,000 shares on July 6, 2026, for $2,445,434, and 30,000 shares on June 1, 2026, for $2,875,107. The aggregate market value for the planned 20,000-share block is listed as $1,978,346.
Mirum Pharmaceuticals (MIRM) Is Down 5.0% After Wider Losses and Volixibat Delay - What's Changed
Mirum Pharmaceuticals (MIRM) reported wider net losses in Q2 2026 and the first half of 2026, despite raising full-year product sales guidance for LIVMARLI. The company's stock fell 5.0% due to these increased losses and a delay in the U.S. filing for its drug volixibat, which was pushed to H1 2027 following an FDA request for another Phase III study. This creates a tension between strong current product sales from LIVMARLI and increased investment and regulatory uncertainty for its pipeline.
Mirum Pharmaceuticals (MIRM) Is Down 5.0% After Wider Losses and Volixibat Delay - What's Changed
Mirum Pharmaceuticals reported wider net losses in Q2 2026, reaching US$857.38 million for the first half of the year, despite raising full-year product sales guidance to US$680-US$700 million. The company's stock fell 5.0% due to these losses and a significant delay in the FDA's approval process for volixibat, pushing its U.S. filing to 2027, which adds uncertainty to its long-term pipeline outlook. While current product LIVMARLI shows strong commercial traction, the increased reliance on this single product and regulatory hurdles for volixibat are key concerns for investors.
Wall Street Zen Upgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to "Hold"
Wall Street Zen has upgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "sell" to "hold" despite broader analyst coverage maintaining a "Moderate Buy" rating with a $137.33 price target. This upgrade comes as Mirum Pharmaceuticals reported better-than-expected second-quarter revenues of $176.24 million, a 37.9% year-over-year increase, though the company missed EPS estimates with a loss of $1.06 per share. Concerns include an unexpected FDA request for a Phase 3 study and recent insider stock sales totaling approximately $7.2 million.
The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM
The Manufacturers Life Insurance Company significantly increased its stake in Mirum Pharmaceuticals (NASDAQ: MIRM) by 63.3% in the first quarter, now holding 55,693 shares valued at $5.15 million. Despite Mirum's Q2 revenue beating estimates at $176.2 million and raised 2026 revenue guidance, the company posted a larger-than-expected adjusted loss of $1.06 per share and faces regulatory hurdles with an FDA request for an additional Phase 3 study. Shares fell about 11%, yet analysts maintain generally positive ratings with a consensus price target of $137.33.
MIRUM PHARMACEUTICALS, INC. : RAYMOND JAMES RAISES TARGET PRICE TO $183 FROM $165
Raymond James has increased its target price for MIRUM Pharmaceuticals, Inc. (MIRUM) from $165 to $183. This update indicates a positive outlook from the financial firm regarding the pharmaceutical company's future performance. The article itself is very brief, consisting only of this announcement.
MIRUM PHARMACEUTICALS, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $140 FROM $185
H.C. Wainwright has reduced its target price for Mirum Pharmaceuticals Inc. (MIRM.O) from $185 to $140. This announcement was made on August 6, 2026, according to a Reuters report published on Bitget News. The article explicitly states that its content reflects the author's opinion and should not be used for investment decisions.
Mirum Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $138.21, Implies 31% Upside
Mirum Pharmaceuticals, Inc.'s average 12-month price target has been lowered to $138.21 from $145.29, according to 14 analysts. Despite the cut, the new target still suggests a 31% potential upside from the Aug. 5 closing price. The consensus rating remains a "Buy" across all covering analysts.
Mirum Pharmaceuticals Slides as FDA Feedback Clouds Volixibat Timeline
Mirum Pharmaceuticals (MIRM) stock dropped 10.4% after the FDA recommended a Phase 3 study for its drug volixibat, delaying its potential NDA submission despite strong second-quarter sales and raised full-year guidance. The regulatory setback for volixibat, intended for cholestatic pruritus due to PSC, has raised investor concerns about the timeline and execution risk for this key pipeline program. Insiders have sold off shares, while institutional investors show mixed activity, with some significantly adding to their holdings.
RBC Capital Adjusts Mirum Pharmaceuticals PT to $135 From $148, Maintains Outperform Rating
RBC Capital has lowered its price target for Mirum Pharmaceuticals (MIRM) from $148 to $135, while still maintaining an Outperform rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, which showed a wider loss despite increased revenue. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, with key products like LIVMARLI and Cholbam.
FMR LLC reveals 6.2% Mirum Pharmaceuticals (MIRM) ownership in Schedule 13G
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 3,777,851.04 shares of Mirum Pharmaceuticals Inc. (MIRM) common stock, which represents 6.2% of the class. Abigail P. Johnson also holds sole dispositive power over the same number of shares. The filing indicates that while other persons may receive dividends or sale proceeds, no single person other than FMR LLC and Abigail P. Johnson holds more than five percent of the outstanding common stock.
Mirum Pharmaceuticals Q2 2026 Earnings Call Transcript
Mirum Pharmaceuticals reported strong Q2 2026 results, with net product sales of $176 million, and raised its full-year guidance to $680 million-$700 million. The company is preparing for the potential Q4 U.S. launch of zilurgisertib for FOP, following a favorable FDA meeting. However, the FDA recommended an additional Phase III study for volixibat in PSC, delaying its NDA filing to H1 2027, despite Mirum's disagreement and the drug's breakthrough therapy designation.
Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%
Shares of Mirum Pharmaceuticals (MIRM) dropped 15% after the FDA requested an additional Phase 3 trial for its lead candidate, Volixibat, delaying its potential new drug application until the first half of 2027. Despite this setback, the company raised its full-year 2026 net product sales guidance and reported better-than-expected Q2 revenue. Citizens maintained an 'Outperform' rating but lowered its price target, while some retail investors viewed the stock's slump as an 'overreaction' and a buying opportunity.
Mirum Pharmaceuticals (MIRM) SVP sells 1,840 shares under 10b5-1 plan
Jolanda Howe, SVP and Global Controller at Mirum Pharmaceuticals (MIRM), sold 1,840 shares of common stock on August 3, 2026, at a price of $105.29 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following the sale, Howe directly holds 1,274 shares of Mirum Common Stock.
Mirum Pharmaceuticals (MIRM) Earnings Date and Reports 2026
Mirum Pharmaceuticals (MIRM) announced its Q2 2026 earnings on August 5, 2026, reporting an EPS of -$1.06, missing the consensus estimate of -$0.74. Despite the EPS miss, quarterly revenue increased by 37.9% year-over-year to $176.24 million, exceeding the consensus estimate of $166.33 million. The company's earnings are projected to improve significantly next year, with EPS expected to grow from ($4.42) to ($0.30) per share.
MIRM (NASDAQ: MIRM) holder files notice to sell common shares
A holder of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) common stock has filed a notice to sell 1,840 shares through Morgan Stanley Smith Barney LLC on or after August 3, 2026. The filing also reports prior sales by Jolanda Marie Howe, including 2,721 shares on July 1, 2026, and 2,594 shares on June 17, 2026. The proposed sale will be executed on NASDAQ.
Mirum Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRM
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) generated $521.31 million in revenue last year, primarily from its Pharmaceutical segment. This represents an increase from $336.41 million in the previous year. The United States was the largest contributor to revenue, accounting for $401.55 million last year.
MIRM5806400 Bond Coupon Profile — Rate & Payments
This page provides the bond coupon profile for Mirum Pharmaceuticals, Inc. (MIRM5806400), detailing its interest rate and payment schedule. The bond has a current coupon rate of 4.00%, with the next payment planned for November 2, 2026. It offers an overview of the bond's nominal yield and encourages users to unlock full data for more insights.
Liquidity Mapping Around (MIRM) Price Events
Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) is showing weak near and mid-term sentiment, despite a positive long-term outlook. AI models have generated three distinct trading strategies for MIRM, including position trading, momentum breakout, and risk hedging, with detailed entry points, targets, and stop losses. The analysis highlights a mid-channel oscillation pattern and a significant risk-reward short setup.
Hear Mirum Pharmaceuticals' second-quarter update Aug. 5
Mirum Pharmaceuticals (Nasdaq: MIRM) announced it will report its second-quarter 2026 financial results on August 5, 2026. The company will also host a conference call on the same day to discuss these results and recent corporate developments. Mirum Pharmaceuticals is a rare disease company with approved products and a pipeline of investigational medicines for rare liver and genetic diseases.
Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis
Mirum Pharmaceuticals Inc (MIRM) has a current valuation score of 9.66, placing it 11th out of 155 companies in the Pharmaceuticals industry. Its P/E ratio is -7.91, which is below its recent high and above its recent low. However, relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
Mirum Pharmaceuticals (Nasdaq: MIRM) will announce its second-quarter 2026 financial results on August 5, 2026. The company will also host a conference call on the same day at 4:30 p.m. ET to discuss these results and recent corporate developments. Mirum is a rare disease company with approved products and a pipeline of investigational medicines.
